This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Multi-center, Open-Label, Adaptive, Randomized S...
Clinical trial

A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Na�ve Patients with Extens

Read time: 1 mins
Last updated:9th Mar 2012
The primary objective of this study is to compare the efficacy of palifosfamide-tris in combination with carboplatin and etoposide (PaCE) chemotherapy to carboplatin and etoposide (CE) alone, as measured by overall survival (OS), in chemotherapy na�ve subjects with extensive-stage SCLC.
Category Value
Study start date 2012-03-09

View full details